Highlights Recap | Realbio Exhibits at the 2024 CACLP, Empowering the New Chapter of IVD Development with Innovations

From March 16th to 18th, the 21st China International Laboratory Medicine and Blood Transfusion Instrument and Reagent Expo (CACLP) opened grandly at the Chongqing International Expo Center!

CACLP is an important platform for academic exchanges and business negotiations for the global IVD community. This year's expo was themed "Cooperation and Sharing, Wisdom Guiding the Future," discussing the trend of technological innovation, showcasing the latest achievements, and exchanging cutting-edge technologies, leading the future development direction of the laboratory medicine and IVD industry.

Over the course of three days, Ruiyi Biotech showcased its medical device-certified products, multiple cancer gene methylation products, and health products. In-depth discussions and exchanges were held with numerous partners and manufacturers, co-creating a new chapter in the IVD industry!

Based on China's cancer incidence and screening status, as a national high-tech enterprise specializing in tumor precision detection, Ruiyi Biotech focuses on innovative R&D and continuously overcomes technical barriers in early cancer detection. The two core certified products - Changyi Shu® colorectal cancer early non-invasive detection product and Dula Guan® fecal occult blood (FOB) detection reagent (colloidal gold immunoassay) - are significant practical achievements of Ruiyi's transition from clinical research to industrialization. With their technical expertise, product maturity, and wide market application, they have attracted the attention of many visiting clients.

At the expo, Ruiyi showcased significant breakthroughs in early cancer detection. Starting with colorectal cancer, Ruiyi is gradually transitioning from single-cancer to multi-cancer research and development. The in-development pipelines on display cover multiple high-incidence cancer types, including digestive system tumors (liver cancer, esophageal cancer, gastric cancer), reproductive system tumors (cervical cancer), urinary system tumors (bladder cancer), and respiratory system tumors (lung cancer). This aims to further advance the window for cancer prevention and treatment, helping more high-risk groups seize the "golden window period" for clinical intervention.

This exhibition attracted over 1300 in vitro diagnostic industry-related companies from both domestic and overseas, with over 100,000 attendees. Ruiyi Biotech, with its industry reputation and innovative products and services, drew numerous visiting clients who came to visit during the exhibition. The atmosphere on site was continuously high, with visitors coming and going incessantly.

Ruiyi's business personnel engaged in in-depth communication and business negotiations with the visiting clients, providing detailed explanations of the product and service features and performance indicators, and sharing the company's innovative achievements in recent years. The visiting clients also showed great interest and reached several cooperation intentions.